Medium impact
Asparlas™ (calaspargase pegol-mknl) (Revised)
Humana·Effective Dec 1, 2025
Humana Medicaid Louisiana has revised its prior authorization policy for Asparlas (calaspargase pegol-mknl), a chemotherapy drug for acute lymphoblastic leukemia (ALL) in patients age ≤21 years. The policy clarifies approval criteria requiring ALL diagnosis, use in multi-agent chemotherapy regimens, and age restrictions, while identifying five specific exclusions (disease progression on Asparlas, history of serious thrombosis/pancreatitis/hemorrhage with prior asparaginase therapy, and elevated bilirubin >10x upper limit of normal). Prior authorization is required for all Asparlas claims under this plan.